The comparison that matters between these four platforms is not primarily the length of each company's regulatory-clearance list, though that list is genuinely relevant, it is how the system fits the radiologist's actual reporting workflow: what it flags, how it prioritises, where it sits in the reading process, and whether adopting it demonstrably changes reporting time or downstream care rather than simply adding another window to a busy screen.
The comparison, dimension by dimension
Modalities supported: platforms differ in whether they cover CT, chest X-ray, or a broader multi-modality range, a foundational compatibility question before anything else matters. Single-abnormality versus multi-finding analysis: some tools are built around detecting one specific critical finding reliably, others attempt broader multi-finding coverage across a study, a genuine trade-off between depth and breadth. Worklist prioritisation: whether the platform reorders which studies a radiologist sees first based on detected urgency, a workflow-level intervention distinct from per-image detection accuracy. Measurement and preliminary report generation: increasingly common extensions beyond flagging, quantifying findings and drafting report language for radiologist review. Care coordination: notification and communication features that route urgent findings to the right clinical team quickly, a function whose value depends on institutional integration as much as algorithmic accuracy. NHS and international deployments, regulatory breadth: the practical footprint each platform has achieved varies considerably and should be checked against your specific territory and modality needs rather than assumed uniform. False-alert burden: the unglamorous metric that determines whether a platform gets trusted or ignored in daily use, a high false-positive rate erodes exactly the vigilance the tool exists to support. Integration with PACS and RIS: whether the platform slots into existing radiology infrastructure smoothly or requires disruptive workflow change. Evidence of reporting-time or outcome improvement: the rung of the evidence ladder that separates a platform proven to detect findings from one proven to actually improve the service using it.
The four platforms, broadly positioned
Aidoc has built its proposition around enterprise-wide detection, prioritisation and workflow integration, positioning itself less as a single-finding detector and more as infrastructure spanning many findings and care-coordination functions. Annalise.ai has developed multi-finding analysis across chest X-ray and CT, aiming at breadth of detection within those modalities. Qure.ai has built particularly strong offerings in chest X-ray interpretation, tuberculosis screening and stroke-related analysis, a portfolio shaped partly by global health applications where these conditions carry high burden. Lunit has prominent products in chest radiography and breast imaging specifically, concentrating depth in those two areas. Their current product portfolios and territory-specific regulatory indications differ materially from each other and change over time, which makes rechecking current scope directly against each company's published indications, rather than relying on a general reputation, the responsible approach before any procurement decision.
The Breakthrough Device caution, stated precisely
A specific and instructive caution belongs in this comparison: Aidoc's 2026 "First Read" report-drafting product received FDA Breakthrough Device designation, and designation should never be described as FDA clearance. The two are different regulatory events, designation signals that the FDA considers the technology promising and has agreed to prioritise its review, clearance means that review process has concluded favourably for a stated indication, and coverage or marketing language that uses "FDA breakthrough" and "FDA cleared" interchangeably is making exactly the compression error this cluster's regulatory-literacy piece exists to correct, a caution worth generalising to any product across this category carrying a designation rather than a completed clearance.
What actually decides platform choice
Rarely the headline clearance count, more often the specific workflow fit: which modalities and findings matter most to a given service's case mix, whether the platform's prioritisation logic integrates cleanly with existing PACS and reporting systems, and whether any published evidence addresses reporting time or downstream outcomes rather than detection accuracy alone. A platform with narrower regulatory breadth that fits a service's actual workflow and case mix precisely may deliver more real value than a broader platform bolted onto infrastructure it integrates with poorly, which is why this comparison resists naming an overall winner and instead offers the dimensions worth scoring locally.
Frequently asked questions
Does a longer list of FDA clearances mean a platform is more clinically valuable?
Not necessarily: clearance count reflects breadth of authorised indications, and clinical value depends equally on workflow fit, false-alert burden and evidence of reporting-time or outcome improvement, none of which a clearance count captures directly.
What should "Breakthrough Device designation" change about how a claim is read?
It should be read as an FDA signal of prioritised review for a promising technology, not as evidence the technology has completed clearance or approval; the underlying clinical evidence still needs to be assessed on its own terms.
How should a radiology department pilot one of these platforms fairly?
Against its own case mix and existing PACS integration, measuring false-alert burden and reporting-time impact directly during the pilot, rather than relying on vendor-reported figures from a different institution's deployment.